Marimastat: BB 2516, TA 2516

Author：  

Publisher： Adis International

ISSN： 1174-5886

Source： Drugs in R&D, Vol.4, Iss.3, 2003-01, pp. : 198-203

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Marimastat: the clinical development of a matrix metalloproteinase inhibitor

By Thomas A.L.   Steward W.P.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 12, 2000-12 ,pp. : 2913-2922

Informa Healthcare

Access to resources Recommend Favorite

The Therapeutic Potential of 4-1BB (CD137) in Cancer

By  

Current Cancer Drug Targets, Vol. 5, Iss. 5, 2005-08 ,pp. : 357-363

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Recombinant Human Platelet-derived Growth Factor-BB (rhPDGF-BB) in Orthopaedic Bone Repair and Regeneration

By  

Current Pharmaceutical Design, Vol. 19, Iss. 19, 2013-06 ,pp. : 3384-3390

Bentham Science Publishers

Access to resources Recommend Favorite

Hyaluronic acid/Chitosan nanoparticles as delivery vehicles for VEGF and PDGF-BB

By Parajó Yolanda   d’Angelo Ivana   Welle Alexander   Garcia-Fuentes Marcos   Alonso1 María José  

Drug Delivery, Vol. 17, Iss. 8, 2010-11 ,pp. : 596-604

Informa Healthcare

Access to resources Recommend Favorite

Anti-4-1BB cancer gene therapy shows potential

By  

Inpharma, Vol. 1, Iss. 1336, 2002-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite